var data={"title":"Fluorescein: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluorescein: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6212?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">see &quot;Fluorescein: Drug information&quot;</a> and <a href=\"topic.htm?path=fluorescein-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluorescein: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172390\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AK-Fluor;</li>\n      <li>Bio Glo;</li>\n      <li>Fluor-I-Strips A.T.;</li>\n      <li>Fluorescite;</li>\n      <li>Ful-Glo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172391\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fluorescite</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1014564\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45068904\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>Ophthalmic angiography for retinopathy of prematurity (ROP):</b> Limited data available: PMA &ge;30 weeks: IV: Usual reported dose: 10 mg/kg (0.1 mL/kg of 10% solution) as a single dose followed by a saline flush; reported range: 7.7 to 10 mg/kg/dose (Azad 2008; Lepore 2011; Lepore 2014) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1014576\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">see &quot;Fluorescein: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic staining:</b> Limited data available: Infants, Children, and Adolescents: Ophthalmic: Strips: Moisten strip with sterile water, saline, or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained (Kliegman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ophthalmic angiography:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Test dose:</i> Infants, Children, and Adolescents: Intradermal: Prior to use, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30 to 60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Diagnostic dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Limited data available: IV: Reported range: 7.7 to 10 mg/kg as a single dose followed by a saline flush (Azad 2008; Lepore 2011; Lepore 2014; Tahija 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 7.7 mg/kg (actual body weight) as a single dose into antecubital vein; maximum dose: 500 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic staining:</b> Ophthalmic: Strips: Moisten strip with sterile water, saline, or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ophthalmic angiography:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution for injection: <b>Note:</b> Prior to use, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30 to 60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 500 mg as a single dose into antecubital vein; a dose of 200 mg may be appropriate in cases when a highly sensitive imaging system (eg, scanning laser ophthalmoscope) is used. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172384\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AK-Fluor: 10% (5 mL); 25% (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluorescite: 10% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Strip, Ophthalmic, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio Glo: 1 mg (100 ea, 300 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluor-I-Strips A.T.: 1 mg (300 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ful-Glo: 0.6 mg (300 ea); 1 mg (100 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172373\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5192545\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Strips: In infants, children, adolescents, and adults, fluorescein impregnated tip should be moistened prior to application. Strip should be applied to conjunctiva or fornix. For best results, patient should blink several times after application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: In infants, children, adolescents, and adults, a 23-gauge butterfly needle inserted into an antecubital vein attached to a small syringe is suggested for administration. Prior to turning off room light, steps should be taken to ensure the needle has not extravasated. Immediate treatment for anaphylaxis (including epinephrine 1 mg/mL) should be available and premedication or a test dose may be advised in some patients. Inject the dose over 5 to 10 seconds. Luminescence appears in the eye 7 to 30 seconds following injection. Maintain venous access following procedure in the event treatment is needed for anaphylaxis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095153\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at controlled room temperature; protect from freezing. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic strips: Store at controlled room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1014565\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Diagnostic aid in ophthalmic angiography and angioscopy of the retina and iris vasculature (AK-Fluor: FDA approved in children and adults; Fluorescite: FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Staining of the anterior segment of the eye for diagnostic purposes (eg, ophthalmic procedures such as fitting contact lenses, disclosing corneal injury, and in applanation tonometry) (OTC: Bio Glo, Ful-Glo: Approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172422\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reactions associated with use of the injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arterial ischemia (basilar; rare), hypotension, shock, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Convulsions (rare), dizziness (Kwan 2006), headache, nerve palsy (localized; [Kwan 2006]), seizure (rare; [Kwan 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, rash at injection site, skin discoloration (yellow), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia, gastrointestinal distress, nausea (common), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration (bright yellow)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemolytic anemia (Kwan 2006), sickle cell disease (Kwan 2006, Acheson 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Extravasation, inflammation at injection site</p>\n    <p style=\"text-indent:0em;\">Respiratory: Bronchospasm, pulmonary edema (acute; [Kwan 2006])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172387\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluorescein or any other component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172377\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur (death has been reported rarely); immediate treatment (including epinephrine) should be available. Serious intolerance reactions may be induced; history of adverse reaction to fluorescein or allergic reaction to foods or drugs, such as urticaria, asthma, eczema, or allergic rhinitis, may increase risk. Premedicating some patients (eg, antihistamines, corticosteroids) may be advisable. An intradermal skin test may be performed prior to use when allergy is suspected; however, a negative skin test does not rule out the potential for a reaction to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection; these reactions usually subside within 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin/urine discoloration: Following use of the injection, skin may temporarily turn a yellow color within a few minutes of administration and usually fades in 6 to 12 hours. Urine may appear bright yellow for 24 to 36 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies/asthma: Respiratory reactions may occur, especially in patients with a history of allergies or bronchial asthma; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Contact lens wearers: Ophthalmic products should not be used in patients with soft contact lenses, will cause them to discolor. Flush eyes with saline following use and wait at least 1hour prior to replacing contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: For administration via antecubital vein only; not for intrathecal or arterial injection. Avoid extravasation; severe local tissue damage may result, including skin sloughing, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. Following extravasation, severe pain may last up to several hours. Discontinue immediately if extravasation occurs.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299351\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220438\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105145&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172380\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095147\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Pregnancy outcome information is available following fluorescein use in pregnant women (Halperin 1990; Olk 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45068905\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Injection: Observe for signs and symptoms of hypersensitivity reactions during procedure and after; monitor injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172376\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluorescein sodium, a fluoresce dye, responds to wavelengths between 465-490 nm of electromagnetic radiation and light, and fluoresces at wavelengths of 520-530 nm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15405175\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapidly metabolized to fluorescein monoglucuronide (~80% is metabolized 1 hour following IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; systemic clearance essentially complete 48 to 72 hours after dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323157\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluorescite Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (5 mL): $55.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Bio Glo Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $14.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Fluor-I-Strips A.T. Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (300): $77.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Ful-Glo Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (300): $36.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $14.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172388\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aka-Fluor (PE);</li>\n      <li>Cendo Fluorescein (ID);</li>\n      <li>Colircusi Fluoresceina (ES);</li>\n      <li>Fluocyne (FR);</li>\n      <li>Fluoftal (AT);</li>\n      <li>Fluor-I-Strip (NL);</li>\n      <li>Fluoralfa (IT);</li>\n      <li>Fluore Stain Strips (IN);</li>\n      <li>Fluorescein (DE, HR);</li>\n      <li>Fluoresceina (BR);</li>\n      <li>Fluoresceina Oculos (ES);</li>\n      <li>Fluoresceine (IL, LU);</li>\n      <li>Fluoresceine Ophtadose (BE);</li>\n      <li>Fluoresceine SDU Faure (CH);</li>\n      <li>Fluoresceinnatrium (SE);</li>\n      <li>Fluorescite (AE, AR, AU, BF, BH, BJ, CI, CN, CY, CZ, EC, EE, EG, ET, GH, GM, GN, HK, HN, IL, IQ, IR, JO, KE, KR, KW, LB, LR, LV, LY, MA, ML, MR, MU, MW, MY, NE, NG, NZ, OM, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Fluorets (AE, GB, HK, MT, MY, QA, SA);</li>\n      <li>Flurocin (BD);</li>\n      <li>Flyuurestsyt (UA);</li>\n      <li>Minims Fluorescein Sodium (FI, GB);</li>\n      <li>Minims Fluoresceine (BE);</li>\n      <li>Ophth-fluorstrip (PK);</li>\n      <li>Optifluor Diba (MX);</li>\n      <li>Retinofluor (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    AK-FLUOR injection (flourescein) [prescribing information]. Lake Forest, IL: Akorn, Inc; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azad R, Chandra P, Khan MA, Darswal A. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. <i>J Pediatr Ophthalmol Strabismus</i>. 2008;45(1):36-39.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BIOGLO strip (flourescein) [prescribing information]. Rancho Cucamonga, CA: HUB Pharmaceuticals, LLC; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluorescite injection, solution (flourescein) [prescribing information]. Lake Forest, IL: Akorn, Inc; July 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluorets ophthalmic strips (flourescein) [prescribing information]. Rochester, NY: Bausch &amp; Lomb Incorporated. October, 2009</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ful-Glo ophthalmic strips(flourescein) [prescribing information]. Lake Forest, IL: Akorn, Inc; March 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hara T, Inami M, and Hara T. &ldquo;Efficacy and Safety of Fluorescein Angiography With Orally Administered Sodium Fluorescein,&rdquo; <i>Am J Ophthalmol</i>, 1998, 126(4):560-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/9780101/pubmed\" target=\"_blank\" id=\"9780101\">9780101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan AS, Barry C, McAllister IL, et al, &ldquo;Fluorescein Angiography and Adverse Drug Reactions Revisited: The Lions Eye Experience,&rdquo; <i>Clin Experiment Ophthalmol</i>, 2006, 34(1):33-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/16451256/pubmed\" target=\"_blank\" id=\"16451256\">16451256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepore D, Molle F, Pagliara MM. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. <i>Ophthalmology</i>. 2011;118(1):168-175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/20709401 /pubmed\" target=\"_blank\" id=\"20709401 \">20709401 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. <i>Ophthalmology</i>. 2014;121(11):2212-2219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/25001158 /pubmed\" target=\"_blank\" id=\"25001158 \">25001158 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. <i>Br J Ophthalmol</i>. 2014;98(4):507-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/24403566 /pubmed\" target=\"_blank\" id=\"24403566 \">24403566 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105145 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172390\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172391\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1014564\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F45068904\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1014576\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172384\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F172373\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5192545\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5095153\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1014565\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172422\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172387\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172377\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299351\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220438\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172380\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5095147\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45068905\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172376\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F15405175\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323157\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172388\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105145|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluorescein-drug-information\" class=\"drug drug_general\">Fluorescein: Drug information</a></li><li><a href=\"topic.htm?path=fluorescein-patient-drug-information\" class=\"drug drug_patient\">Fluorescein: Patient drug information</a></li></ul></div></div>","javascript":null}